Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Innovation Pharmaceuticals Inc. (IPIX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2800+0.0360 (+14.75%)
At close: 3:59PM EDT
Advertisement
Sign in to post a message.
  • J
    Joseph
    What does the new 8k filing show that was released 1 hour ago? Anything worthwhile? Says a change in directors has taken place.
  • m
    monique
    From Palm Beach paper.. But, Huxtable said, another medication that hasn’t gotten FDA approval is being used to treat COVID-19 patients. Drock signed a special release so his wife could receive the drug Brilacidin, he told Nutt.
  • g
    georgejjl
    Regarding the recent 8K filing

    Is it possible and even probable that Innovation Pharmaceutical’s board of directors knows more about what is happening with Brilacidin than those on this discussion board???

    Good for thought!!!

    Good luck and GOD bless,
  • T
    Tyrone
    September 23, 2021
    Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin’s Broad-Spectrum Antiviral Properties
    Brilacidin
    WAKEFIELD, MA / September 23, 2021 / ACCESSWIRE Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897), as well as related news.

    Based on information received from the data management and biostatistics vendors, study unblinding, analysis of the unblinded data and release of topline study results for the Brilacidin COVID-19 trial is anticipated to occur in mid-to-late October. The Company looks forward to the data to learn if Brilacidin’s multiple properties translate into meaningful clinical results, given the unmet need for COVID-19 therapeutics and ongoing pandemic.

    In related news, the Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin. In addition to Brilacidin’s antiviral profile, Brilacidin’s immunomodulatory and anti-inflammatory properties may be particularly beneficial in treating COVID-19 in hospitalized patients.
  • e
    emr
    Awaiting the

    ClinicalTrials dot gov Identifier: NCT04784897

    status change.
    Bullish
  • R
    Reality
    Hey crazy eddie and the rest of the Aspire Capital flunkies: Did you read Bloomberg Opinion Money Stuff today, or is that too high brow for your boiler room? Enjoy the head fake on Friday? Brought to you by the pump and dump specialists from Aspire Capital (AC). Better stay out of Down Under, a sister Commonwealth country crazy eddie. Because the Australia Securities and Investment Commission has posted on stock chat boards “coordinated pumping of shares can be illegal.” Oops Then the ASIC said: “We can see all trades and have access to trader identities. We’re monitoring this platform and we may be investigating you. You run the risk of a criminal record, including fines of more than $1M and prison time by being involved.” Info from Bloomberg Opinion "Money Stuff."
  • g
    g1
    So.. How about them Braves?
  • t
    thonas
    Productive day.
  • t
    thonas
    The last 15yrs does not matter to the people holding long here. It’s the next few days or week that matters right now. Think future not passed. GLTA
  • t
    thonas
    Leadtone you must realize that the people here are holding for whatever the outcome is on phase 2. A 20 cent stock will make us a lot of money or loose a little money. It’s called risk and reward. GLTAL
  • t
    thonas
    Leadtone and his cronies are in there final stages of negativity then then good news comes and they change there names on this board and become happy shareholders. GLTA
  • m
    mike
    Its the middle of October, I am waiting on news any day now like they said......
  • m
    masonb
    $ 1 or More Coming Soon !
  • g
    georgejjl
    NEXT WEEK???

    Good luck and GOD bless,
    Bullish
  • S
    Sherman
    Minimum 20 Bagger from here 💴
    Bullish
  • C
    Coppertone
    Could the IPIX SCAM close this week above a full QUARTER after only 15 YEARS?
  • T
    Tyrone
    The Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin.
  • S
    Sherman
    Tic Tic Tic Tic
    Bullish
  • g
    gayle siebern
    Concerns about molnupiravir’s cost
    Merck’s shiny new Covid-19 pill, molnupiravir, may reduce hospitalization risk dramatically — but concerns are already swirling around how much, if authorized, the antiviral will cost.

    In June, the U.S. government signed a $1.2 billion deal with Merck for 1.7 million doses of the drug, which was developed jointly with Ridgeback Biotherapeutics. That works out to a $712 unit cost for a five-day treatment course.

    “With 100,000 new infections per day in the U.S., a unit price of $700 per treatment course would create a huge burden on budgets if this drug was used to prevent new infections as well,” one pharmacologist who is studying monupiravir pricing told STAT. Meantime, by one estimate, the actual manufacturing expense for molnupiravir is about $20.
  • g
    gayle siebern
    Last June, the U.S. government signed a $1.2 billion deal with Merck for 1.7 million doses, which works out to a $712 unit cost for a five-day treatment course, according to the contract. This assumes the U.S. Food and Drug Administration will authorize emergency use of the pill. Separately, the company has indicated there are plans to produce 10 million doses by the end of this year.

    For the moment, Wall Street analysts say the sales potential is uncertain, since Pfizer (PFE) and Roche (RHHBY) are running late-stage trials of their own pills and could provide stiff competition in coming months. And Merck, which has exclusive worldwide rights to market molnupiravir, has not yet disclosed pricing in the U.S., because the drug is not yet available.

    Nonetheless, there is already debate about the cost to American taxpayers and their health care system.

    One reason is that the actual manufacturing cost for a five-day treatment course is estimated to be $20, which is a fraction of the unit cost, according to a new estimate by Melissa Barber, a doctoral candidate in the Department of Global Health and Population at Harvard University, and Dzintars Gotham, a World Health Organization consultant.
Advertisement
Advertisement